Paolo Tarantino: A new ADC is now available to treat the most common subtype of breast cancer
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X:
“A new ADC is now available to treat the most common subtype of breast cancer.
Datopotamab deruxtecan (Dato-DXd), which targets Trop2 and delivers DXd, is approved for pretreated patients with HR+/HER2- MBC, after outperforming chemo in the TB01 trial.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He completed a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023